[{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"b2c9ef7d-2fb3-45a4-a86b-257c668139cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03767582","created_at":"2021-02-23T17:53:27.774Z","updated_at":"2025-02-25T14:27:51.862Z","phase":"Phase 1/2","brief_title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","source_id_and_acronym":"NCT03767582","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9","pipe":"","alterations":" ","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-12-10"},{"id":"37f445e0-3beb-40a4-8567-9de16b5cc533","acronym":"PICCASSO","url":"https://clinicaltrials.gov/study/NCT03274804","created_at":"2021-01-17T18:04:47.498Z","updated_at":"2024-07-02T16:36:09.249Z","phase":"Phase 1","brief_title":"Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC","source_id_and_acronym":"NCT03274804 - PICCASSO","lead_sponsor":"University Hospital Heidelberg","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-06-07"},{"id":"d0b6a163-4818-41af-9aae-cc62ea1a993c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03838367","created_at":"2021-01-18T18:56:51.338Z","updated_at":"2024-07-02T16:36:15.074Z","phase":"Phase 1/2","brief_title":"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC","source_id_and_acronym":"NCT03838367","lead_sponsor":"CytoDyn, Inc.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vyrologix (leronlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/22/2019","start_date":" 04/22/2019","primary_txt":" Primary completion: 07/15/2022","primary_completion_date":" 07/15/2022","study_txt":" Completion: 09/16/2022","study_completion_date":" 09/16/2022","last_update_posted":"2022-03-21"},{"id":"6fd84c97-f385-402f-96cc-d8585cf1e544","acronym":"","url":"https://clinicaltrials.gov/study/NCT04313075","created_at":"2021-01-18T20:54:24.625Z","updated_at":"2024-07-02T16:36:17.832Z","phase":"","brief_title":"A Compassionate Use Study of Leronlimab in Breast Cancer","source_id_and_acronym":"NCT04313075","lead_sponsor":"CytoDyn, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyrologix (leronlimab)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-01-28"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"},{"id":"ffc131aa-8b13-4488-9640-fb3e7099359c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01785810","created_at":"2021-01-18T07:53:06.683Z","updated_at":"2024-07-02T16:36:36.243Z","phase":"Phase 2","brief_title":"Phase II Maraviroc for GVHD Prevention","source_id_and_acronym":"NCT01785810","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 11/11/2016","primary_completion_date":" 11/11/2016","study_txt":" Completion: 07/12/2018","study_completion_date":" 07/12/2018","last_update_posted":"2021-01-11"}]